Improving the Quality of Care for Patients with Asthma
Pulmonary Disease
Curriculum:
Improving the Quality of Care for Patients with Asthma
Improving the Quality of Care for Patients with Asthma
Credits:
2.75 ACPE 3 CA-BRN Credit(s) 2.75 AMA PRA Category 1 Credit(s) ™
2.75 ACPE 3 CA-BRN Credit(s) 2.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
May 29, 2013
May 29, 2013
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Community pulmonologists, family and internal medicine physicians, physician assistants, nurse practitioners, respiratory therapists, pharmacists, and other health care professionals who treat patients with asthma.
Relevant Terms:
Asthma
Michael Wechsler, MD
Michael Wechsler, MD (Program Chair)
Director, Asthma Program
Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health
Denver, Colorado
Bio
David Beuther, MD
David Beuther, MD
Chief Medical Information Officer
Assistant Professor
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, Colorado
Bio
Rohit Katial, MD
Rohit Katial, MD
Program Director, Allergy & Immunology – Adult Program
Director, Weinberg Clinical Research Unit
Director, Allergy and Immunology Clinical Services
Professor, Division of Allergy and Clinical Immunology
Department of Medicine
National Jewish Health
Denver, Colorado
Bio
| 1. | Describe guideline-concordant therapy for asthma control, including the management of difficult to control asthma | 2. | Discuss the relative advantages and disadvantages associated with various asthma pharmacotherapies |
| 3. | Recommend non-pharmacological therapies as appropriate | 4. | Discuss how to effectively communicate with patients to address barriers and apply evidence-based strategies to non-adherent patients |
| 5. | Describe how to individualize the selection of asthma regimens based on patient profile and preferences |
| 1. | Describe guideline-concordant therapy for asthma control, including the management of difficult to control asthma |
| 2. | Discuss the relative advantages and disadvantages associated with various asthma pharmacotherapies |
| 3. | Recommend non-pharmacological therapies as appropriate |
| 4. | Discuss how to effectively communicate with patients to address barriers and apply evidence-based strategies to non-adherent patients |
| 5. | Describe how to individualize the selection of asthma regimens based on patient profile and preferences |
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., Stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
Faculty Disclosures
Dr. David Beuther discloses that he is a speaker for Merck & Co., Inc.
Dr. Rohit Katial discloses that he is on the advisory board for Teva.
Dr. Esther Langmack does not have any finanacial interest to disclose.
Dr. Harold Nelson discloses that he is a consultant for Merck, Shionogi, Pearl Pharmaceuticals and an investigator for Lincoln Diagnostics, Rigel, Circassia.
Dr. Harold Nelson discloses that he is a consultant for Merck, Shionogi, Pearl Pharmaceuticals and an investigator for Lincoln Diagnostics, Rigel, Circassia.
Dr. Michael Wechsler discloses that he is a consultant for Boston Scientific, Cytos, GlaxoSmithKline, Medimmune, Merck, Novartis, Teva.
DISCLOSURE ATTESTATION
All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
DISCLAIMER
The National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
CREDIT DESIGNATION
Continuing Medical Education Accreditation and Designation
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Jewish Health designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education for Nurses
National Jewish Health is an approved provider of continuing nursing education by the California Board of Registered Nursing. Provider Number 12724. The entire conference is approved for a total of 3.0 Nursing Contact Hours.
Participant attendance throughout an entire conference segment is required to receive contact hours.
Continuing Education for Respiratory Therapists
This program has been approved for a maximum of 2.75 contact hours Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063
Course #140357000
Course #140357000
Continuing Education for Pharmacists
National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. National Jewish Health designates this live activity for 2.75 contact hours (0.275 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0831-0000-13-003-L01-P
Universal Activity Number: 0831-0000-13-003-L01-P
Type of Activity: Knowledge-Based
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, attendees are entitled to receive CME/CE credits.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Participants who successfully complete the post-test and evaluation will receive CME/CE credit. You must complete the post-test and evaluation to receive credit for this activity.
COURSE VIEWING REQUIREMENTS
Google Chrome for Windows, Mac, or Linux
Internet Explorer 8.0+ for Windows
Mozilla 1.4+ for Windows, Mac, or Linux
Firefox 3.5+ for Windows, Mac, or Linux
Safari 4.0+ for Mac
Release Date: 5-29-2013
Google Chrome for Windows, Mac, or Linux
Internet Explorer 8.0+ for Windows
Mozilla 1.4+ for Windows, Mac, or Linux
Firefox 3.5+ for Windows, Mac, or Linux
Safari 4.0+ for Mac
Release Date: 5-29-2013
Expiration Date: 6-7-2013
COMMERCIAL SUPPORT
This program is sponsored by National Jewish Health and is supported by educational grants from AstraZeneca, Boehringer Ingelheim, Merck and Sunovion.
